Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis India: An update - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Nov 9, 2001

    Novartis India: An update

    Novartis India has gone through a major restructuring exercise in the last one year. The company has hived off/ discontinued its loss making businesses and vertically integrated its operations. The results of the same are now becoming apparent.

    Novartis Restructuring Exercise- How it helped
    Dec’99 De-merged Seed/Agri business into Syngenta India Ltd in line
    with global operations. Though this was a profit making division,
    revenues to a large extent were dependent on the monsoons.
    April'00 Ciba CKD Biochem was merged with the company.
    The merger with Ciba CKD has given control to Novartis over
    its raw material required for its anti-TB business.
    Oct’00 Introduced a new division viz, Consumer Healthcare to take advantage
    of growing OTC market in India. The idea being to provide
    a fillip to the company’s topline growth.
    Jan'01 Ciba Vision business- a lens care business was closed down.
    The ophthalmic division of Ciba Vision transferred to Novartis India.
    The lens care business was a drag on the company’s profitability.

    In its latest quarterly results (Sept’01 ended), the company far outperformed its peers in terms of operating profit margins. While average operating margins of MNC pharma companies improved by around 100 basis points, Novartis recorded more than a 1,000 basis points jump in margins.

    Novartis, now has three distinct business divisions viz, Pharma, animal healthcare and consumer healthcare (OTC). In the pharma business the company has presence in both mass category (anti-inflammatory, anti-TB segment) as well as super specialty segments (like neurology, Cardiovascular, oncology).

    Though Novartis has launched four new products in the last six months, sales growth from the pharma business remained flat, growing at 2.7% in the concerned period against an average Pharma MNC growth of around 4%. This was mainly on account of competition from new generation molecules for its flagship anti-inflammatory brand ‘Voveran’ (which contributes around 20% of its turnover) and higher import duty on its immuno suppressant “ sandimmum” brand (which contributes around 10% of its turnover).

    Pharma business commands operating margins of around 23%, which is the best amongst all pharma MNC companies. However, topline growth remains a problem.

    Novartis- Division wise Breakup
    1HFY02 Sales (Rs.m) Growth % Margins %*
    Pharma 1970 2.70% 22.80%
    Consumer Health 199 24.40% 4.50%
    Animal Healthcare Business 186 40.90% 16.40%
    * Profit before interest and tax

    In the consumer healthcare division the company has presence in two major categories viz. cough/cold preparations (Otrivin, Tavegyl) and vitamins/mineral supplements (Calcium Sandoz, Sandocal, Hematrine and Nutrisan). The ‘Calcium Sandoz’ and ‘Otrivin’ brand are leaders in their respective segments.

    The newly established consumer healthcare division is showing healthy growth albeit on a smaller base. However, the operating margins in this segment were under severe pressure due to high brand building exercises and severe price competition in the segment. The animal healthcare business is also growing at an encouraging rate of above 40%, with fairly good operating margins.

    On the financial front, Novartis is expected to make considerable interest cost savings, as the company repays its debt of around Rs 948 m from sale of property (at Goregoan) and internal accruals. The sale of land is expected to accrue Rs 725 m over a period of four years.

    The fact remains that in the pharma business the company has presence in niche specialty segments and its products command respectable market share in their respective therapeutic segment. However, the company is heavily dependent on some core brands (Tegretol, Voveran and Sandimmum) for its revenues, which together contribute a major chunk of its revenues.

    It is clear that the growth in the pharma business is purely subject to new product introductions from the parent’s stable. However, the parent company seems uncomfortable to introduce new drugs in India until patent protection is granted.

    To summarise, the restructuring exercise undertaken by the company has certainly yielded results but going forward the challenge for the company is two fold.

    • Improve topline growth in the pharma business
    • Make Consumer Healthcare business profitable.

    At the current market price of Rs 240, the stock trades 11x our expected earnings for FY02, which is at a discount to its peers.



    Equitymaster requests your view! Post a comment on "Novartis India: An update". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts